drugset / Trial / NCT03324373
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to see what effect the combination of lenvatinib plus everolimus has in local and metastatic renal cell carcinoma to potentially make surgically unresectable tumors resectable.
Timeline
- Start
- 2019-03-20
- Primary completion
- 2023-09-27
- Completion
- 2024-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Lenvatinib | Small molecule | 18 mg | Oral |